Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Net Cash Flow: 2023-2025

Historic Net Cash Flow for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to -$3.0 million.

  • Artiva Biotherapeutics' Net Cash Flow fell 113.68% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.2 million, marking a year-over-year decrease of 259.68%. This contributed to the annual value of -$13.3 million for FY2024, which is 72.93% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Net Cash Flow of -$3.0 million as of Q3 2025, which was down 53.13% from -$1.9 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Net Cash Flow high stood at $21.6 million for Q3 2024, and its period low was -$15.6 million during Q4 2024.
  • For the 3-year period, Artiva Biotherapeutics' Net Cash Flow averaged around -$2.9 million, with its median value being -$5.3 million (2024).
  • The largest annual percentage gain for Artiva Biotherapeutics' Net Cash Flow in the last 5 years was 84.33% (2025), contrasted with its biggest fall of 113.68% (2025).
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Net Cash Flow stood at -$12.4 million in 2023, then dropped by 26.37% to -$15.6 million in 2024, then plummeted by 113.68% to -$3.0 million in 2025.
  • Its Net Cash Flow was -$3.0 million in Q3 2025, compared to -$1.9 million in Q2 2025 and -$9.6 million in Q1 2025.